Educational Webcast Series Targeted to the Interprofessional Bladder Cancer Care Team Improves Clinician Knowledge, Confidence, and Competence.

e23002 Background: There are an estimated >81,000 new cases of metastatic urothelial bladder cancer (mUBC) diagnosed in the U.S each year, resulting in more than 17,000 deaths. mUBC has been shown to be susceptible to immune checkpoint inhibitors (ICIs), and beyond currently approved first and second line indications, these agents are being studied in bladder-sparing regimens and for high risk NMIBC patients who are BCG-unresponsive. Needs assessments demonstrate educational gaps involved in medication selection, dosing, and immune-related adverse event management as barriers to immunotherapy use by the interprofessional bladder cancer care team. The webcast series, “Key Issues for the Advanced Bladder Cancer Care Clinic: Incorporating Immunotherapy into your Community-Based Urology Practice” was designed specifically for the interprofessional team of bladder cancer clinicians to address unmet educational needs by focusing on the communities where the significant majority of patients are diagnosed, evaluated, and managed. Methods: Four online activities were designed to target urology and uro-oncology community physicians, physician assistants, nurse practitioners, nurses, and pharmacists focused on ICI therapies for bladder cancer, with a focus on the role of the team. Learning and confidence change were objectively assessed by analyzing pre- and post-test results before and after the educational activities. Statistical testing between pre- and post-tests were conducted via chi square analysis with a priori significance set at 0.05. Results: Evaluations were collected from N=706 participants. Knowledge advancements, as determined by significant ( P<0.05) increases in correct responses, were observed in several specific topic areas: recognition of ongoing clinical trials (29% pre-test vs. 69% post-test) biomarkers and treatment selection (43% pre-test vs. 81% post-test) logistical concerns for patients initiating ICIs (60% pre-test vs. 80% post-test) Participant self-reported mean confidence scores increased with statistical significance in implementation of appropriate immunotherapy and in recognizing and mitigating irAEs from pre- to post-test ( P<0.05). Conclusions: As the treatment paradigm for bladder cancer continuously evolves, all members of the oncology healthcare team must be equipped to evolve with it to ensure optimal patient care. This analysis shows that online accredited education can significantly improve the knowledge and confidence of the interprofessional bladder cancer care team in multiple areas surrounding the effective and appropriate use of ICIs.